# A Study of RO4917523 in Patients With Fragile X Syndrome

> **NCT01517698** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 185 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO4917523 0.5 mg
- **DRUG:** RO4917523 1.5 mg

## Key facts

- **NCT ID:** NCT01517698
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517698, "A Study of RO4917523 in Patients With Fragile X Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01517698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*